## INDOCO REMEDIES LIMITED

Regd. Office: Indoco House, 166, CST Road, Santacruz (E), Mumbai 400 098

## AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2011

(`in lakhs)

			(	in lakhs)
٥-				Year ended
Sr.	Particulars	Year ended		31.03.2010
No.		31.03.2011 (Audited)		(Audited)
		,		`
1	(a) Sales and Income from Operations	48,356		40,231
	Less : Excise Duty	(509)		(402)
	Net Sales and Income from Operations	47,847		39,829
	(b) Other Operating income	795		431
	Total	48,642		40,260
2	Expenditure :	,		,
	(a) (Increase)/Decrease in Finished Goods, Stock in trade and			
	Work in progress	(1,189)		(593)
	(b) Consumption of raw materials	19,306		15,404
	(c) Purchase of traded goods	3,198		2,521
	(d) Employees cost	6,702		5.646
	(e) Depreciation	1,345		1,210
	(f) Research & Development Expenses	934		1,022
	(q) Other Expenditure	12.452		10.462
	Total	42,748		35,672
,		42,740		35,672
3	Profit from Operations before Other Income, Interest and Exceptional Items	5,894		4,588
4	Other Income	5,094		<b>4,366</b>
	Profit before Interest and Exceptional Items	5,899		4,604
	•			
	Interest	240		291
	Profit after Interest but before Exceptional Items	5,659		4,313
	Exceptional Items			- 4 040
	Profit from Ordinary Activities before tax	5,659		4,313
10	Tax Expenses - Current	1,128		731
	- Deferred	147		126
	- Prior Year	-		(22)
	- MAT Credit	(728)		(731)
	Net Profit from Ordinary Activities after tax	5,112		4,209
	Extraordinary Items			
	Net Profit for the period	5,112		4,209
	Paid up Equity Share Capital (Face value ` 10/- eac			1228.67
	Reserves excluding Revaluation Reserves	33,791		29,822
16	Earning Per Share (EPS) (`)			
	(a) Basic and diluted EPS before Extraordinary Items	41.60		34.26
	(b) Basic and diluted EPS after Extraordinary Items	41.60		34.26
17	Public shareholding			
	- No of Shares	47,95,103		48,57,636
	- % of Shareholding	39.03		39.53
18	Promoters and promoters group shareholding			
	a) Pledged/Encumbered			
	- Number of shares	8,200		8,200
	- Percentage of shares (as a % of the total	0.11		0.11
	shareholding of promoter and promoter group)			
	- Percentage of shares (as a % of the total share	0.07		0.07
	capital of the company)			
	b) Non-encumbered		1	
	- Number of shares	74,83,411		74,20,878
	- Percentage of shares (as a % of the total	99.89		99.89
	shareholding of promoter and promoter group)			
	- Percentage of shares (as a % of the total share	60.90		60.40
	capital of the company)		L	

## Notes:

(`in lakhs) 1 STATEMENT OF ASSETS & LIABILITIES AS ON 31ST MARCH, 2011

Particulars	Year ended 31.03.2011 (Audited)	Year ended 31.03.2010 (Audited)
SHAREHOLDERS' FUNDS:		
(a) Capital	1,229	1,229
(b) Reserves and Surplus	33,791	29,822
LOAN FUNDS	9,994	6,604
DEFERRED TAX	2,572	2,425
TOTAL	47,586	40,080
FIXED ASSETS	29,480	22,791
INVESTMENTS	2	2
CURRENT ASSETS, LOANS AND ADVANCES		
(a) Inventories	8,042	6,912
(b) Sundry Debtors	9,179	9,071
(c) Cash and Bank balances	2,705	3,755
(d) Loans and Advances	6,913	5,370
Less: Current Liabilities and Provisions		
(a) Liabilities	7,098	6,366
(b) Provisions	1,638	1,460
MISCELLANEOUS EXPENDITURES (NOT WRITTEN OFF OR ADJUSTED)	1	5
PROFIT AND LOSS ACCOUNT	0	(
TOTAL	47 586	40.080

- TOTAL

  The company has only one primary reportable segment of activity, namely, Pharmaceuticals.
  The above results have been reviewed by the Audit Committee and taken on record at the meeting of Board of Directors held on 28th May, 2011.

  The Board has recommended payment of dividend of `8/- per equity share of `10/- each for the year ended 31.03.2011, subject to the approval of members at ensuing Annual General Meeting. The figures for the previous year have been regrouped and reclassified, wherever necessary. Summary of investor complaints: As on 01.4.2010:Nil, Received during year:17, Resolved:17, Pending as on 31.03.2011:Nil.
- 4
- 5 6

By Order of the Board

Place: Mumbai Date: May 28, 2011 Suresh G. Kare Chairman & Managing Director